Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT ID: NCT06007690 Phase: PHASE3 Sponsor: Aura Biosciences Status: Active Not Recruiting

SUMMARY

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).

KEY ELIGIBILITY CRITERIA

- * Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL/CM)
- * Have no evidence of metastatic disease confirmed by imaging
- * Be treatment naive for IL/CM (subjects who received PDT may be eligible)
- * Have known contraindications or sensitivities to the study drug or laser
- * Active ocular infection or disease

Total sites: 53 | 0 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT06007690) and public sources. Generated by FindMyCure.ai.